Form 4 Filing for Kiniksa Pharmaceuticals International, plc

This filing details Form 4 transactions for Kiniksa Pharmaceuticals International, plc, on April 7, 2026. Michael R. Megna, Chief Accounting Officer, reported the acquisition of 3,932 Class A Ordinary Shares through the vesting of Restricted Share Units (RSUs), with each RSU representing a contingent right to one Class A Ordinary Share. These RSUs vest over a four-year period, with 25% vesting annually starting from April 7, 2022. Additionally, Megna reported the disposal of 1,666 Class A Ordinary Shares at a price of $48.94 per share. Following these transactions, the post-transaction share ownership for Megna is reported as 35,709 shares after acquisition and 34,043 shares after disposal.